Table 3.
Multivariable regression for primary and secondary outcomes from SECURE‐IBD cohort
| ICU/vent/death | Hospitalization or death | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||||
| Variable (referent group) | n (%) | Odds ratio (95% CI) | P | Odds ratio (95% CI) | P | n (%) | Odds ratio (95% CI) | P | Odds ratio (95% CI) | P |
| Age | 1.03 (1.00–1.06) | 0.03 | 1.01 (0.97–1.04) | 0.80 | 1.04 (1.02–1.06) | <0.001 | 1.03 (1.00–1.05) | 0.04 | ||
| Sex | ||||||||||
| Male | 6 (6.5) | 1.00 | 20 (21.7) | |||||||
| Female | 11 (8.0) | 1.25 (0.47–3.51) | 0.67 | 27 (19.7) | 0.88 (0.46–1.69) | 0.71 | ||||
| Diagnosis | ||||||||||
| Crohn's disease (ulcerative colitis/IBD unspecified) | 6 (5.2) | 1.00 | 21 (18.3) | |||||||
| UC/unspecified | 11 (9.6) | 1.92 (0.69–5.38) | 0.21 | 26 (22.6) | 1.31 (0.69–2.49) | 0.41 | ||||
| Disease severity | ||||||||||
| Remission | 6 (5.4) | 18 (16.2) | ||||||||
| Active disease (active/moderate/severe) | 11 (9.3) | 1.80 (0.64–5.04) | 0.26 | 29 (24.6) | 1.68 (0.87–3.22) | 0.12 | ||||
| Systemic corticosteroid | ||||||||||
| No | 7 (3.5) | 28 (14.1) | ||||||||
| Yes | 10 (31.3) | 12.40 (4.29–35.87) | <0.001 | 10.97 (3.44–34.99) | <0.001 | 19 (59.4) | 8.87 (3.94–19.96) | <0.001 | 9.33 (3.84–22.63) | <0.001 |
| TNF antagonist | ||||||||||
| No | 11 (8.0) | 30 (21.7) | ||||||||
| Yes | 6 (6.5) | 0.81 (0.29–2.26) | 0.68 | 17 (18.5) | 0.82 (0.42–1.59) | 0.55 | ||||
| Current smoker | ||||||||||
| No | 16 (7.2) | 45 (20.2) | ||||||||
| Yes | 1 (14.3) | 2.16 (0.24–19.02) | 0.49 | 2 (28.6) | 1.58 (0.30–8.42) | 0.59 | ||||
| BMI>30 | ||||||||||
| No | 11 (8.5) | 40 (21.2) | ||||||||
| Yes | 1 (5.0) | 0.57 (0.07–4.53) | 0.59 | 4 (20.0) | 0.93 (0.30–2.94) | 0.90 | ||||
| Comorbidities | ||||||||||
| None | 7 (4.0) | 26 (14.7) | ||||||||
| 1 | 5 (11.6) | 3.20 (0.96–10.61) | 0.06 | 3.03 (0.83–11.10) | 0.94 | 13 (30.2) | 2.52 (1.16–5.45) | 0.02 | 2.14 (0.89–5.15) | 0.09 |
| ≥2 | 5 (50.0) | 24.29 (5.69–103.73) | <0.001 | 17.31 (2.56–116.85) | 0.003 | 8 (80.0) | 23.23 (4.67–115.57) | <0.001 | 10.70 (1.74–65.72) | 0.01 |
| 5‐ASA/sulfasalazine | ||||||||||
| No | 6 (9.7) | 16 (25.8) | ||||||||
| Yes | 11 (6.5) | 0.65 (0.23–1.85) | 0.42 | 31 (18.5) | 0.65 (0.32–1.30) | 0.22 | ||||
| 6MP/azathioprine monotherapy | ||||||||||
| No | 12 (6.0) | 41 (20.5) | ||||||||
| Yes | 5 (16.7) | 3.13 (1.02–9.64) | 0.05 | 4.54 (1.11–18.63) | 0.04 | 6 (20.0) | 0.97 (0.37–2.54) | 0.95 | ||
5‐ASA, 5 aminosalicylate acid drugs; 6MP, mercaptopurine; BMI, body mass index; CD, Crohn's disease; CI, confidence interval; IBD, inflammatory bowel disease; ICU, intensive care unit; UC, ulcerative colitis; Vent, ventilator.